Catalog No.
Product Name
Application
Product Information
Citations
-
VHL-linker Isomer
(S,S,S)-AHPC-PEG2-NH2 is a VHL-linker isomer designed for targeted protein degradation applications. This compound serves as a component in the synthesis of PROTACs, facilitating the selective ubiquitination and degradation of target proteins. It is particularly relevant for research in leukemia and other related hematological malignancies, providing a valuable tool for investigating protein function and therapeutic potential. -
E3 Ligase Ligand-Linker Conjugates
A 410099.1 amide-PEG3-amine-Boc is a functionalized IAP ligand specifically designed for use in PROTAC technology, featuring an IAP ligand coupled with an amide-PEG3 linker that contains a terminal amine group. This compound facilitates the conjugation of target protein ligands, making it suitable for research applications involving targeted protein degradation. Its unique structure allows for enhanced specificity and efficiency in E3 ligase recruitment, contributing to advancements in therapeutic drug development and cellular biology studies. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 166 is a specialized conjugate that combines an E3 ligase ligand with a linker, facilitating targeted protein degradation. This compound is instrumental in the synthesis of PROTAC CDK9 degrader-11, serving as a valuable tool for studying targeted degradation pathways. Its application in research contributes to the exploration of novel therapeutic strategies for modulating protein levels in various biological contexts. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-N-methylpiperazine is an E3 ligase ligand-linker conjugate that facilitates targeted protein degradation through the PROTAC (Proteolysis Targeting Chimeras) approach. This compound is employed in the synthesis of PROTAC MLKL Degrader-2, demonstrating antinecroptotic activity in human cell lines and effectively degrading MLKL in HT-29 xenograft mouse models. Its applications are pivotal in understanding necroptosis and exploring therapeutic strategies in related diseases. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 213 is a specialized linker conjugate designed to engage E3 ubiquitin ligases, specifically CRBN. This dual-functional compound combines an E3 ligase ligand with a linker, facilitating the development of targeted protein degradation strategies. Its primary applications include drug discovery and the synthesis of proteolysis targeting chimeras (PROTACs), such as PSP-0119, enhancing the modulation of protein turnover in cellular contexts. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 136 is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound facilitates the synthesis of c-Myc inhibitor 7, enabling the study of c-Myc-related signaling pathways and the development of innovative therapeutic strategies. Its unique mechanism allows for the precise modulation of protein levels, which is critical for functional assays in cancer research and other biochemical investigations. -
E3 Ligase Ligand-linker Conjugate
Pomalidomide-C9-Br is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTAC EGFR degrader 15, a targeted protein degradation agent. This compound exhibits significant anti-cancer activity by promoting the degradation of epidermal growth factor receptor (EGFR) through the proteasome pathway. The use of Pomalidomide-C9-Br in research applications may accelerate the development of novel therapeutics aimed at treating EGFR-driven malignancies. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-C3-NH2 is an E3 ligase ligand-linker conjugate designed to engage cereblon, leveraging the properties of Pomalidomide. This compound facilitates the development of PROTAC (Proteolysis Targeting Chimera) strategies, enabling targeted protein degradation. Its unique composition allows for enhanced cellular uptake and efficacy in modulating protein levels, making it valuable for research in drug discovery and therapeutic applications related to protein regulation. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C5-azacyclohexane-N-Boc is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. It facilitates the synthesis of XD2-149, enabling researchers to investigate the modulation of E3 ligase activity and its biological effects. This compound supports studies in chemical biology, therapeutic development, and the exploration of ubiquitin-proteasome system interactions. -
Ligand for E3 Ligase
Pomalidomide-5-C7-NH2 hydrochloride is a synthetic ligand targeting the E3 ligase cereblon (CRBN). This compound facilitates the recruitment of CRBN, enabling the innovative design of PROTACs (Proteolysis Targeting Chimeras) for targeted protein degradation studies. Its unique chemical structure supports the exploration of CRBN's role in various cellular processes and therapeutic applications, such as oncology and autoimmune diseases. -
Protein Ligand
Lenalidomide 4'-alkyl-C5-azide is a functionalized cerebellar ligand designed for the development of PROTACs. This compound features an E3 ligase ligand and a long-chain alkyl group with terminal azides, facilitating the conjugation with target protein ligands. It serves as an important tool for researchers investigating targeted protein degradation and related pathways in cellular models. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-linker Conjugate 141 is a conjugate designed for interaction with E3 ubiquitin ligases, facilitating the development of proteolysis-targeting chimeras (PROTACs). This compound is integral for synthesizing PROTAC ER Degrader-12, which selectively degrades estrogen receptors. Researchers can utilize this conjugate in studies focused on targeted protein degradation and drug discovery, particularly in the context of cancer therapy and hormone-related disorders. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-amido-PEG2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that utilizes Thalidomide as a cereblon-targeting ligand combined with a PEG-based linker. This compound is designed for applications in PROTACs (proteolysis-targeting chimeras), facilitating targeted protein degradation for therapeutic interventions. Its specific mechanisms enable the modulation of protein levels within cells, making it a valuable tool for investigating cellular pathways and developing novel treatments. -
Click Chemical Reagent
Lenalidomide 4'-alkyl-C3-azide is a click chemical reagent that incorporates an azide group into lenalidomide, facilitating the synthesis of PROTACs. As an orally active immunomodulator, lenalidomide acts as a ligand for the ubiquitin E3 ligase cereblon (CRBN). This compound is capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAC) reactions with alkyne-containing molecules, as well as strain-promoted azide-alkyne cycloaddition (SPAAC) with DBCO or BCN groups, thereby enabling versatile modifications in chemical biology research. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-azetidin-3-one is an E3 ligase ligand-linker conjugate that facilitates targeted protein degradation. This compound is instrumental in the synthesis of the PROTAC PD-L1 degrader-2, enabling researchers to investigate therapeutic strategies for modulating immune responses through PD-L1 degradation. Its incorporation into PROTAC design holds potential for advancing cancer immunotherapy research. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 185 is designed as a specific E3 ligase ligand-linker conjugate. This compound facilitates the development of PROTACs (Proteolysis Targeting Chimeras) by enabling targeted degradation of proteins through the recruitment of E3 ligases. Its applications extend to various fields including cancer research, pharmacology, and drug discovery, where it helps in studying protein regulation and therapeutic targeting. -
E3 Ligase Ligand-Linker Conjugate
(S,S,R)-AHPC-C6-NH2 is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound facilitates the development of proteolysis-targeting chimeras (PROTACs) by linking target proteins to E3 ligases, enhancing selective degradation pathways in cellular models. It is instrumental in advancing research in targeted therapy and studying cellular processes related to protein homeostasis. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 165 is a specialized conjugate composed of an E3 ligase ligand and a linker, designed for use in the synthesis of PROTAC SJ44236. This compound facilitates targeted protein degradation by promoting the ubiquitination of specific proteins, thereby enhancing the study of protein function and regulation in various biological contexts. Its application is crucial in the development of novel therapeutic strategies that leverage the ubiquitin-proteasome system. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 51 is a conjugate that incorporates a Thalidomide-derived E3 ligase ligand with a linker component. This compound functions as a ligand for Cereblon, effectively facilitating the recruitment of the CRBN protein. E3 Ligase Ligand-Linker Conjugate 51 is crucial for the synthesis of complete PROTAC (Proteolysis Targeting Chimeras) molecules, making it valuable for research in targeted protein degradation and related therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-PEG2-C2-boc is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound facilitates the synthesis of PROTAC YAP degrader-1, enabling efficient modulation of protein levels through the ubiquitin-proteasome pathway. It is valuable for research in targeted therapeutic strategies and the study of protein homeostasis in various biological systems. -
E3 Ligase Ligand-Linker Conjugate
BTK ligand 11-alcohol-PEG6-azido is a synthetic E3 ligase ligand-linker conjugate designed for the development of proteolysis-targeting chimeras (PROTACs). This compound facilitates the targeted degradation of proteins by linking the E3 ligase to the target protein, enhancing the specificity and efficacy of the degradation process. Its applications in research include the study of protein regulation and the modulation of cellular pathways involved in various diseases. -
E3 Ligase Ligand-Linker Conjugate
Me-Thalidomide-O-C8-NH2 is an E3 ligase ligand-linker conjugate that facilitates targeted protein degradation. This compound demonstrates key biological activity in modulating E3 ubiquitin ligase interactions, which is essential for the development of novel therapeutic strategies. It serves as a valuable intermediate in the synthesis of MS154N, contributing to research in drug discovery and cellular regulation pathways. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 58 functions as a conjugate of E3 ligase ligand and linker, incorporating Thalidomide as its ligand. This compound effectively recruits the Cereblon (CRBN) protein, making it an essential intermediate for the synthesis of complete PROTAC (proteolysis-targeting chimera) molecules. Its application in targeted protein degradation research highlights its significance in advancing therapeutic strategies in various diseases. -
E3 Ligase-Linker Conjugate
trans-Thalidomide-1,4-cyclohexanediamine is an E3 ligase-linker conjugate utilized in the synthesis of PROTACs. This compound serves as a crucial building block for developing PROTACs, such as CL-F-B1, which demonstrates potent activity in degrading PD-L1 and has significant anticancer effects. Its application in PROTAC technology facilitates targeted degradation of specific proteins, making it valuable in cancer research and therapeutic development. -
E3 Ligase Ligand-Linker Conjugates Chemical
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-C5-Br is an E3 ligase ligand-linker conjugate specifically designed for use in PROTAC (Proteolysis Targeting Chimera) technology. This compound facilitates targeted proteolysis by recruiting E3 ligases, enabling the selective degradation of specific proteins within cellular environments. Its role in modulating protein levels makes it a valuable tool for research in targeted protein degradation and therapeutic applications related to cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Phthalimidinoglutarimide-piperidine-NH2 is an E3 ligase ligand-linker conjugate that comprises a Thalidomide moiety. This compound functions as a Cereblon ligand, facilitating the recruitment of the CRBN protein. It plays a crucial role as an intermediate in the synthesis of complete PROTAC molecules, making it valuable for research in targeted protein degradation and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugates
AhR Ligand-Linker Conjugates 1 is designed as an E3 ubiquitin ligase ligand-linker conjugate that incorporates an IAP (inhibitor of apoptosis) ligand alongside a SNIPER (Specific and Pioneering IAP-medited Protein elimination) linker. This reagent enables the targeted degradation of specific proteins through the recruitment of E3 ligases. Its applications extend to drug discovery and the study of protein regulation through the ubiquitin-proteasome system, facilitating advancements in therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
Me-(S,R,S)-AHPC-CO-C5-N3 is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound combines a VHL ligand with a specialized linker, facilitating the synthesis of PROTACs. Its utility in developing PROTACs, such as PROTAC CG167, underscores its relevance in chemical biology and therapeutic research focused on protein regulation. -
E3 Ligase Ligand-Linker Conjugates
Phenyl-glutarimide 4'-oxyacetic-amide-C5-amide-Boc is a specialized E3 ligase ligand-linker conjugate designed for use in the synthesis of targeted protein degradation compounds, such as PROTAC SJ995973. This reagent facilitates the development of bifunctional molecules that can selectively induce the ubiquitination of target proteins, thereby enhancing the efficiency of protein degradation research. Its utility in proteolysis-targeting chimera (PROTAC) studies makes it a valuable tool for exploring new therapeutic strategies in various biological systems. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-Linker Conjugate 188 functions as a ligand-linker conjugate specifically for E3 ligases. This compound is utilized in the synthesis of AZ'3137, facilitating the study of targeted protein degradation and cellular signaling pathways. Its distinctive design enables researchers to explore the roles of E3 ligases in various biological processes and drug development applications. -
E3 Ligase Ligand-Linker Conjugate
Pom-8PEG is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. It features a cereblon (CRBN) ligand that facilitates interaction with the E3 ubiquitin ligase, connected via an 8-unit polyethylene glycol (PEG) linker. This compound serves as a crucial component in the synthesis of Proteolysis Targeting Chimeras (PROTACs), enabling specific degradation of target proteins, including potential applications in the development of IDO1 PROTAC degraders. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-PEG4-C2-NH2 TFA is an E3 ligase ligand-linker conjugate that combines the Pomalidomide-derived cereblon ligand with a four-unit polyethylene glycol (PEG) linker. This compound serves as a critical component in PROTAC (proteolysis-targeting chimeras) technology, facilitating targeted protein degradation. Its design enables efficient recruitment of E3 ubiquitin ligases, enhancing the regulation of protein levels in research applications focused on protein homeostasis and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 15 is a novel conjugate designed for use with E3 ubiquitin ligases. This reagent facilitates the synthesis of complete PROteolysis TArgeting Chimeras (PROTACs), enabling targeted protein degradation. Its application is crucial for researchers investigating protein dynamics and therapeutics aimed at modulating cellular pathways through ubiquitin-mediated degradation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C2-2-azaspiro[3.3]heptane is a conjugate designed for targeting E3 ubiquitin ligases and serves as a linker component in the development of bifunctional degradation technologies. This compound plays a crucial role in the synthesis of KT-413, facilitating selective protein degradation for research applications in cancer and other diseases. Its unique structure enhances ligand-receptor interactions, offering valuable insights into E3 ligase biology and therapeutic targeting. -
HyT and Linker Conjugates
2-(2-Aminoethoxy)ethyl 2-(adamantan-1-yl) acetate serves as a hybrid compound that integrates a hydrophobic group with a linker. This reagent is essential for the synthesis of SARD279, a compound that can be utilized in various research applications including cell signaling and protein interaction studies. Its unique structure facilitates the development of targeted therapy strategies in chemical biology. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-C2-PEG-NHCO-C2-COOH targets cereblon (CRBN) and functions as an E3 ligase ligand-linker conjugate. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs) for the selective degradation of proteins, specifically enabling the development of the ASK1 degrader dASK1. It is valuable for research in targeted protein degradation and E3 ligase modulation. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-phenylacetic acid is an E3 Ligase Ligand-Linker Conjugate designed for targeted protein degradation applications. This compound serves as a critical building block for the synthesis of PROTAC SMARCA2/4-degrader-15, facilitating the ubiquitination and degradation of specific target proteins. Its utility in PROTAC development underscores its significance in advancing therapeutic strategies in cellular regulation and protein homeostasis studies. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C5-NH2 is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. It combines a VH032-derived VHL ligand with a linker specifically for the estrogen-related receptor α (ERRα) PROTAC system. This compound facilitates the formation of complex structures that promote the ubiquitination and subsequent degradation of ERRα, thereby enabling in-depth studies on its biological functions and potential therapeutic interventions. -
E3 Ligand
(S,R,S)-AHPC-O-PEG1-propargyl is an E3 ligand utilized for the synthesis of proteolysis-targeting chimeras (PROTACs). This compound features an alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAC) reactions with azide-containing molecules. Its primary applications include facilitating targeted protein degradation studies and drug discovery efforts in chemical biology. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 201 is a synthesized compound designed to target E3 ligases, facilitating the development of Proteolysis Targeting Chimeras (PROTACs). This reagent is instrumental in the advancement of targeted protein degradation strategies and can be utilized for the synthesis of various PROTACs, including PROTAC ER Degrader-3. Its application in research supports efforts to modulate protein levels and explore therapeutic pathways in cellular contexts. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidine is an E3 Ligase Ligand-Linker Conjugate that facilitates the formation of targeted protein degradation systems. This compound serves as a crucial component in the synthesis of SMART1, enabling precise modulation of protein levels within cellular contexts. Its applications extend to enhancing understanding of protein function and therapeutic development in disease models. -
E3 Ligase Ligand-Linker Conjugates
N-Boc-SBP-0636457-O-C3-COOH is a synthesized E3 ligase ligand-linker conjugate, designed to facilitate targeted protein degradation via PROTAC technology. This compound incorporates an IAP ligand and a linker, enabling the development of Bcl-xL degraders. It is particularly useful in studies aimed at elucidating the role of Bcl-xL in cellular processes and therapeutic applications in cancer research. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 180 is designed to target E3 ubiquitin ligases, facilitating the development of targeted protein degradation strategies. This conjugate enables the synthesis of novel compounds, such as KI-CDK9d-32, and serves as a valuable tool in research focused on modulating protein levels and exploring ubiquitin-proteasome pathways. Its applications extend to investigations in cancer biology, where E3 ligases play critical roles in regulating protein stability and function. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-linker Conjugate 142 is a specialized conjugate designed to target E3 ubiquitin ligases through its ligand-linker structure. This reagent plays a critical role in the development of protein degradation technologies, facilitating the synthesis of CFT8634, a compound of interest in therapeutic research. Its application promotes efficient protein modulation, which is essential for exploring cellular pathways and developing novel drug strategies in the field of cancer therapy and beyond. -
E3 Ligase Ligand-linker Conjugate
Thalidomide-5-F-6-azetidin-MeOH is an E3 ligase ligand-linker conjugate, specifically designed for the synthesis of PROTAC FLT3/CHK1 Degrader-1. This compound effectively targets and degrades FLT3 and CHK1, demonstrating significant anti-tumor activity. It serves as a valuable tool in drug development research, facilitating insights into targeted protein degradation mechanisms in cancer therapy. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-hex-5-ynoic acid is an E3 ligase ligand-linker conjugate designed for the synthesis of Proteolysis Targeting Chimeras (PROTACs). This compound serves as a critical component in the development of targeted protein degradation strategies, exemplified by its role in the PROTAC cGAS degrader-1. Its utility in drug discovery and development research positions it as a valuable tool for investigating protein modulation and pathway exploration. -
VHL Ligand
VH 032 amide-alkylC6-acid is a ligand specifically targeting the von Hippel-Lindau (VHL) protein. As an analog of VH032, it plays a pivotal role in recruiting VHL for various biological processes. This compound is instrumental in the synthesis of PROTACs, facilitating targeted protein degradation for research applications in cancer biology and cellular regulation. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 127 is a targeted E3 ligase ligand-linker conjugate designed for use in the development of PROTAC (Proteolysis Targeting Chimeras) techniques. This compound facilitates the synthesis of the BRM/BRG1 degrader-3, enabling researchers to study targeted protein degradation pathways and E3 ligase interactions. Its application supports advancements in therapeutic strategies for diseases driven by aberrant protein expression. -
E3 Ligase Ligand-linker Conjugate
(S,R,S)-AHPC-C3-NH2 dihydrochloride is a synthesized E3 ligase ligand-linker conjugate, incorporating the VH032-based VHL ligand and a linker utilized in PROTAC (proteolysis-targeting chimera) technology. This compound serves as a critical building block in the synthesis of various PROTACs, including UNC6852, which is a bivalent chemical degrader specifically targeting EED. (S,R,S)-AHPC-C3-NH2 dihydrochloride facilitates investigations into targeted protein degradation, offering valuable insights into protein regulation and potential therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-4-PEG4-OTs is an E3 ligase ligand-linker conjugate designed to target cereblon (CRBN). This compound features a Thalidomide-derived ligand integrated with a four-unit polyethylene glycol (PEG) linker, facilitating the development of proteolysis-targeting chimeras (PROTACs). It is particularly useful in research focused on targeted protein degradation and therapeutic applications involving immune responses.
